Drug intelligence / Profile preview

SCTB41

Development stage: Phase 3
Lead developer: Sinocelltech
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SCTB41 is a trispecific antibody currently in Phase 1/2 clinical development for the treatment of advanced malignant solid tumors. It is administered intravenously and is being evaluated as a monotherapy to assess its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor efficacy. The drug was initially developed by Shenzhou Cell Engineering and is now sponsored by Sinocelltech Group. The precise mechanism of action has not been disclosed[1][4][8].

Beyond the preview

Go deeper on SCTB41.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTB41.

Explore the full profile